ICER Fails People with Alzheimer’s Disease, The Global Alzheimer’s Platform Foundation Calls On Allies to Debunk Report

Washington, DC December 23, 2022–The Institute for Clinical and Economic Review (ICER) has again failed in its attempt to value the benefit provided by a new, life-improving Alzheimer’s treatment, threatening millions of Americans who are living with Alzheimer’s disease.

The report, “Beta-Amyloid Antibodies for Early Alzheimer’s Disease,” released yesterday, advances an analytical framework that ignores the published scientific literature and the rigorous data underpinning lecanemab’s unprecedented performance in delaying the progression of early-stage Alzheimer’s Disease (AD). The AD field needs to debunk ICER’s conclusions. A failure to do so will contribute to the repeated denial of critical, life-improving treatments and therapies for people living with Alzheimer’s disease.  

The Global Alzheimer’s Platform Foundation looks forward to submitting comments that will highlight the flaws in the ICER report. We call on the community of Alzheimer’s clinicians and patient advocates to make clear the true value of therapies that delay the progression of Alzheimer’s and extend the quality of life of people living with this heinous, fatal disease.

To top